10 Biotech Stocks to Buy According to Wall Street Analysts

6. uniQure (NASDAQ:QURE)

Number of Hedge Fund Holders: 35

Average Upside Potential as of July 30: 107.47%

uniQure (NASDAQ:QURE) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 2, uniQure provided a regulatory update on AMT-130, which is the company’s investigational gene therapy for Huntington’s disease, following recent Type B meetings and guidance from the US FDA.

The company has reached alignment with the FDA on key aspects of the statistical analysis plan/SAP and Chemistry, Manufacturing and Controls/CMC information, paving the way for a Biologics License Application/BLA submission, which is now expected in Q1 2026. This accelerated approval pathway is supported by multiple years of clinical data.

Key upcoming milestones for the BLA submission include: submitting the updated SAP to the FDA in Q2 2025, initiating the PPQ run and presenting topline Phase I/II data per the SAP in Q3 2025, and holding a pre-BLA meeting with the FDA in Q4 2025.

uniQure (NASDAQ:QURE) develops treatments for patients suffering from rare and other devastating diseases in the US.